Moderate

Evaluation of proteinuria and albuminuria

proteinuria · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Quantification and characterisation of proteinuria to stratify CKD risk and detect glomerular disease. Albumin:creatinine ratio drives CKD risk classification; nephrotic-range proteinuria or active sediment prompts nephrology referral and possible biopsy.

Red flags

  • Nephrotic-range proteinuria with oedema/hypoalbuminaemia
  • Proteinuria with haematuria/red cell casts and rising creatinine
  • Discordant heavy dipstick proteinuria with low albuminuria (light chains/myeloma)
  • Rapidly rising ACR
  • Proteinuria with systemic features (rash, arthralgia, haemoptysis)

Assessment

Differential diagnosis

  • Glomerular proteinuria (diabetic, hypertensive, glomerulonephritis)
  • Tubular proteinuria (tubulointerstitial disease)
  • Overflow proteinuria (myeloma light chains)
  • Orthostatic/functional proteinuria (benign)
  • Transient proteinuria (fever, exercise, UTI)
  • Nephrotic syndrome from primary/secondary GN

Investigations

  • Urine ACR (preferred) and/or PCR on an early-morning sample
  • Urinalysis/microscopy for haematuria, casts, active sediment
  • Renal function and electrolytes
  • Blood pressure, HbA1c, lipids
  • Serum/urine electrophoresis and free light chains if overflow/myeloma suspected
  • Renal ultrasound; immunological and viral screen if glomerular disease suspected

Management

  • Confirm persistent proteinuria with a quantified early-morning ACR/PCR (not just dipstick), repeating after excluding transient causes (UTI, fever, exercise)
  • Quantify severity: moderately increased (A2) vs severely increased (A3)/nephrotic-range
  • Assess for glomerular disease via urinalysis (haematuria, casts) and clinical context
  • Screen for overflow proteinuria with serum/urine electrophoresis and free light chains if dipstick-ACR discordant or age/risk fits myeloma
  • Identify and treat secondary drivers: diabetes, hypertension, obesity
  • Start an ACE inhibitor or ARB and uptitrate for proteinuric CKD, monitoring potassium and creatinine
  • Add an SGLT2 inhibitor for significant albuminuria/diabetic kidney disease per thresholds
  • Optimise blood pressure to a low target and reduce dietary sodium
  • Refer to nephrology for nephrotic-range proteinuria, active sediment, rapidly rising ACR, or declining eGFR
  • Consider renal biopsy (via nephrology) for unexplained significant glomerular proteinuria
  • Monitor ACR, eGFR, BP and potassium at regular intervals
  • Address cardiovascular risk, which rises with albuminuria

Drugs & doses

Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily (titrate to max tolerated)
Dapagliflozin 10 mg PO once daily (albuminuric/diabetic CKD)
Atorvastatin 20 mg PO once daily (cardiovascular risk)
Finerenone 10-20 mg PO daily (residual albuminuria in diabetic CKD, if K+/eGFR permit)

Disposition

Primary care/CKD clinic for most; nephrology referral for nephrotic-range proteinuria, active sediment or rapid rise. Haematology if myeloma suspected.

Complications & pitfalls

  • Progressive CKD
  • Nephrotic syndrome and its thrombotic/infective complications
  • Cardiovascular events (albuminuria is an independent risk marker)
  • Missed myeloma if overflow proteinuria overlooked
  • AKI from aggressive RAAS blockade in volume depletion

Exam pearls

  • ACR detects albumin (glomerular) better than dipstick; PCR captures total protein including light chains
  • Dipstick heavy but ACR low? Think overflow proteinuria/light chains — send electrophoresis
  • Albuminuria is both a kidney and cardiovascular risk marker
  • Orthostatic proteinuria is benign — confirm with a split day/night collection in young patients
  • RAAS blockade plus SGLT2 inhibition is the core of proteinuria reduction

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.